The OMG! Cancer Summit
Are you a young adult between the ages of 15 and 39 who has been affected by cancer? Are you a caregiver or provider for young adults with cancer? If so, you will want to attend the 3rd annual OMG! Cancer Summit For Young Adults held in New York City on Sunday, May 23rd from 9:00 - 6:00 at Pace University.
The OMG! Cancer Summit is a program presented jointly by the Long Island and New York City chapters of The Leukemia & Lymphoma Society, and the I'm Too Young for This! Cancer Foundation.
The one-day cancer summit is an annual oncology conference and social networking event for those touched by young adult cancer or survivorship issues. Speakers include Ethan Zohn, winner of 2002 Survivor: Africa, and more recently a young adult cancer survivor; Matthew Zachary, founder and CEO of I’m Too Young For This!; Sage Bolte, oncology counselor; and Karen Albritton, MD, young adult oncologist. The best news is that this event is free!
For the full list of speakers and agenda, as well as to register, visit www.omg2010.org.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
